surmount-1 tirzepatide obesity nejm 2022 weight loss percent For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The Tirzepatide: In the SURMOUNT-1 trial,

Mistakes to avoid: Skipping the titration schedule (always start at the lowest dose) Eating large, high-fat meals that worsen nausea Stopping the medication without a tapering plan Not tracking food intake, which makes it hard to identify whats working Choosing a pharmacy without verifying its license or COA availability Follow a semaglutide dosing schedule and pair the medication with a supportive eating plan for best results

Roughly 80% or more of participants on tirzepatide lost more than 5% of their body weight

These can range from nausea, skin and teeth changes, 'Ozempic breath' to genital changes, and even mental health issues

The fix: Make protein non-negotiable

What to Expect Patients may begin to notice weight loss within the first few weeks of treatment, with more significant results over several months

Impact on Fetal Development and Growth One of the most important questions about any medication during pregnancy is how it might affect the baby